Neurocrine biosciences presents data on benztropine use among people treated with antipsychotics at the 2022 american psychiatric nurses association (apna) annual conference

San diego , oct. 19, 2022 /prnewswire/ -- neurocrine biosciences, inc. (nasdaq: nbix) today announced data on the real-world comorbidities, polypharmacy, and treatment patterns of patients on newly prescribed benztropine who were also being treated with antipsychotic medications. this research will be presented at the 2022 american psychiatric nurses association (apna) annual conference being held october 19–22 both virtually and in long beach, ca.
NBIX Ratings Summary
NBIX Quant Ranking